Chonyang Albert

Dr. Chonyang Albert

George M. and Linda H. Kaufman Center for Heart Failure and Recovery, Cleveland Clinic, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2020 in Circulation
Verified
Journal Article
Closed access
PDF file
CAChonyang Albert
Chonyang Albert
ACAndres E. Carmona-Rubio
Andres E. Carmona-Rubio
AWAaron J. Weiss
Aaron J. Weiss
GPGary G. Procop
Gary G. Procop
RSRandall Starling
Randall Starling
ERE. Rene Rodriguez
E. Rene Rodriguez

1 July 2021 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
MGMatthew H. Gonzalez
Matthew H. Gonzalez
QWQiuqing Wang
Qiuqing Wang
DYDmitry M. Yaranov
Dmitry M. Yaranov
CAChonyang Albert
Chonyang Albert
KWKathy Wolski
Kathy Wolski
EJEmer Joyce
Emer Joyce

28 April 2022 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
NINicolas Isaza
Nicolas Isaza
MGMatthew Gonzalez
Matthew Gonzalez
YSYoshihito Saijo
Yoshihito Saijo
MBMaria Vega Brizneda
Maria Vega Brizneda
JEJerry Estep
Jerry Estep
BXBo Xu
Bo Xu

1 March 2021 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
MMMichael Trejeeve Martyn
Michael Trejeeve Martyn
KFKathleen D. Faulkenberg
Kathleen D. Faulkenberg
CAChonyang Albert
Chonyang Albert
ZIZachary J. Il'GIovine
Zachary J. Il'GIovine
VRVarinder K. Randhawa
Varinder K. Randhawa
RSRandall Starling
Randall Starling

3 October 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
WTW.H. Wilson Tang
W.H. Wilson Tang
LTLily Tranchito
Lily Tranchito
CAChonyang Albert
Chonyang Albert
ZGZeynep G. Gul
Zeynep G. Gul
FCFrank S. Cikach
Frank S. Cikach
RDRaed A. Dweik
Raed A. Dweik
Exhaled breath volatile organic compounds (VOCs) are elevated in heart failure (HF). The ability of VOCs to predict long term cardiovascular mortality and morbidity has not been independently verified. In 55 patients admitted with acute decompensated heart failure (ADHF), we measured exhaled breath acetone and pentane levels upon admission and after 48 h of diuresis. In a separate cohort of 51 cardiac patients undergoing cardiopulmonary exercise testing (CPET), we measured exhaled breath acetone and pentane levels before and at peak exercise. In the ADHF cohort, admission acetone levels correlated with lower left ventricular ejection fraction (LVEF, r = −0.297, p = 0.035). Greater weight loss with diuretic therapy correlated with a greater reduction in both acetone levels (r = −0.398, p = 0.003) and pentane levels (r = −0.309, p = 0.021). In patients with above-median weight loss (≥4.5 kg), patients demonstrated significantly greater percentage reduction in acetone (59% reduction vs. 7% increase, p < 0.001) and pentane (23% reduction vs. 2% reduction, p = 0.008). In the CPET cohort, admission acetone and pentane levels correlated with higher VE/VCO2 (r = 0.39, p = 0.005), (r = 0.035, p = 0.014). However, there were no significant correlations between baseline or peak exercise acetone and pentane levels and peak VO2. In longitudinal follow-up with a median duration of 33 months, patients with elevated exhaled acetone and pentane levels experienced higher composite adverse events of death, ventricular assist device implantation, or orthotopic heart transplantation. In patients admitted with ADHF, higher exhaled breath acetone levels are associated with lower LVEF and poorer outcomes, and greater reductions in exhaled breath acetone and pentane tracked with greater weight loss. Exhaled acetone and pentane may be novel biomarkers in heart failure worthy of future investigation.

5 September 2019 in Current Treatment Options in Cardiovascular Medicine
Verified
Journal Article
Closed access
PDF file
CAChonyang Albert
Chonyang Albert